I. Wiethoff

Sikking, M., Wiethoff, I., Henkens, M., Evers, S., Stroeks, S., Venner, M., Weerts, J., Brunner-la Rocca, H.-P., Knackstedt, C., van Empel, V., Michels, M., Heymans, S., Hiligsmann, M., & Verdonschot, J. (2025). High societal costs and reduced health-related quality of life in inflammatory and systemic immune disease-associated dilated cardiomyopathies. Quality of Life Research, 34(10), 2901-2910. https://doi.org/10.1007/s11136-025-04027-5

Wiethoff, I., Schoonvelde, S. A. C., de Boer, R. A., Evers, S. M. A. A., Germans, T., Hirsch, A., Knackstedt, C., Te Rijdt, W. P., van Slegtenhorst, M. A., Schinkel, A. F. L., Zwetsloot, P.-P., Michels, M., & Hiligsmann, M. (2025). Assessing the psychometric properties of generic (EQ-5D-5L) and disease-specific (KCCQ) quality of life in patients with hypertrophic cardiomyopathy in the AFFECT-HCM study. Open Heart, 12(1), Article e003143. https://doi.org/10.1136/openhrt-2024-003143

Schoonvelde, S. A. C., Wiethoff, I., Zwetsloot, P. P., Hirsch, A., Knackstedt, C., Germans, T., Sikking, M., Schinkel, A. F. L., van Slegtenhorst, M. A., Verhagen, J. M. A., de Boer, R. A., Evers, S. M. A. A., Hiligsmann, M., & Michels, M. (2025). Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study. European heart journal - Quality of care & clinical outcomes, 11(2), 174-185. https://doi.org/10.1093/ehjqcco/qcae092

Wiethoff, I., Witlox, W. J. A., Evers, S. M. A. A., Michels, M., & Hiligsmann, M. (2025). Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. Pharmacoeconomics. Advance online publication. https://doi.org/10.1007/s40273-025-01564-2

Wiethoff, I., Goversen, B., Michels, M., van der Velden, J., Hiligsmann, M., Kugener, T., & Evers, S. (2024). Reply to ‘Cost-effectiveness of long term left ventricular assist devices’. Netherlands Heart Journal, 32(12), 463. https://doi.org/10.1007/s12471-024-01910-7

Wiethoff, I., Sikking, M., Evers, S., Gabrio, A., Henkens, M., Michels, M., Verdonschot, J., Heymans, S., & Hiligsmann, M. (2024). Quality of life and societal costs in patients with dilated cardiomyopathy. European heart journal - Quality of care & clinical outcomes, 10(4), 334-344. Article qcad056. https://doi.org/10.1093/ehjqcco/qcad056

Heinz, K. C., Beaudart, C., Willems, D., Wiethoff, I., & Hiligsmann, M. (2023). Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review. Pharmacoeconomics, 41(11), 1415-1435. https://doi.org/10.1007/s40273-023-01293-4

Kugener, T., Wiethoff, I., van Mastrigt, G., van den Berg, B., & Evers, S. M. A. A. (2023). Economic evaluations of interventions focusing on child abuse and neglect in high-income countries: a systematic review. Frontiers in Psychiatry, 14(1), Article 1031037. https://doi.org/10.3389/fpsyt.2023.1031037

Wiethoff, I., Evers, S. M. A. A., Michels, M., & Hiligsmann, M. (2023). An introduction to health technology assessment and health economic evaluation: an online self-learning course. Netherlands Heart Journal, 31(1), 219-225. https://doi.org/10.1007/s12471-023-01777-0

Wiethoff, I., Goversen, B., Michels, M., van der Velden, J., Hiligsmann, M., Kugener, T., & Evers, S. M. A. A. (2023). A systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies. Netherlands Heart Journal, 31(6), 226-237. https://doi.org/10.1007/s12471-023-01776-1